Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5874098 | 0.98 | MAPT (0.48) | SMN1; SMN2NPC1RAB9ATAAR1ALDH1A1 | |
| Pyridine SCHEMBL20535470 | 0.89 | RAB9A (0.48) | SMN1; SMN2NPC1RAB9ATAAR1ALDH1A1 | |
| SCHEMBL20592079 | 0.88 | SIGMAR1 (0.55) | NPC1RAB9AALDH1A1LMNACYP1A2 | |
| SCHEMBL460010 | 0.78 | PTPRF (0.47) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Bromide SCHEMBL17187557 | 0.77 | PTPRF (0.46) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6045117 | 0.77 | MAPT (0.46) | SMN1; SMN2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| Nitric Acid SCHEMBL18329342 | 0.75 | TAAR1 (0.70) | SMN1; SMN2NPC1RAB9ATAAR1ALDH1A1 | |
| Nitric Acid SCHEMBL10789117 | 0.73 | IDO1 (0.45) | SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL28832821 | 0.73 | HDAC2 (0.59) | NPC1RAB9AALDH1A1LMNATSHR | |
| SCHEMBL28487383 | 0.73 | MEN1 (0.75) | SMN1; SMN2NPC1RAB9ATAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1047 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118806889-A | Method for improving adsorption of polysaccharide-protein conjugates and multivalent vaccine formulations obtained therefrom | 印度血清研究所私人有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-09-05 | — | — | US | claimed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | claimed |
| EP-4025246-A2 | IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF | Serum Institute Of India Private Limited (IN) | 2022-07-13 | — | — | EP | claimed |
| CN-114728053-A | Immunogenic compositions against intestinal disease and process for preparing same | 印度血清研究所私人有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-01-13 | — | — | US | claimed |
| EP-3799883-A1 | NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2021-04-07 | — | — | EP | claimed |
| WO-2021044436-A2 | IMMUNOGENIC COMPOSITIONS AGAINST ENTERIC DISEASES AND METHODS FOR ITS PREPARATION THEREOF | SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) | 2021-03-11 | — | — | WO | claimed |
| EP-3664837-A1 | MULTI-FUNCTIONALIZED nOMV CONJUGATES | GlaxoSmithKline Biologicals S.A. (BE) | 2020-06-17 | — | — | EP | claimed |
| EP-3544637-A1 | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2019-10-02 | — | — | EP | claimed |
| WO-2018096013-A1 | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2018-05-31 | — | — | WO | claimed |
| CN-104519910-B | Adjuvanted formulations of streptococcus pneumoniae antigens | 诺华股份有限公司 | 2017-05-03 | — | — | CN | claimed |
| WO-2017067964-A1 | P. AERUGINOSA PCRV-LINKED ANTIGEN VACCINES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-04-27 | — | — | WO | claimed |
| CN-104519910-A | Adjuvanted formulations of streptococcus pneumoniae antigens | NOVARTIS AG | 2015-04-15 | — | — | CN | claimed |
| EP-2822586-A1 | ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS | Novartis AG (CH) | 2015-01-14 | — | — | EP | claimed |
| WO-2013131983-A1 | ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS | NOVARTIS AG (CH) | 2013-09-12 | — | — | WO | claimed |
| EP-2254890-A1 | PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID | Gnosis S.p.A. (IT) | 2010-12-01 | — | — | EP | claimed |
| WO-2009103333-A1 | PROCESS FOR THE DIASTEREOISOMERIC RESOLUTION OF 5-METHYLTETRAHYDROFOLIC ACID | GNOSIS S.P.A. (IT) | 2009-08-27 | — | — | WO | claimed |
| EP-1476197-A2 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-11-17 | — | — | EP | claimed |
| WO-2003070282-A2 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | VAPB, CD14, CHMP4B | SMN1; SMN2 4307/4885NPC1 380/4885RAB9A 297/4885 |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | CD14, VAPB, CHMP4B | SMN1; SMN2 4171/4885NPC1 384/4885RAB9A 290/4885 |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | CD14, CHMP4B, VAPB | SMN1; SMN2 4243/4885NPC1 390/4885RAB9A 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.